All GLG News Analyses Filed Under: Oncology

This study is notable for several reasons: (1) it looked at 2 dose of BIBF 1120 and found essentially no difference in tumor control between the higher and lower dose regimens; (2) it included only patients who had previously received chemotherapy, and therefore, by definition, were less likely to have...

Antibodies are formed by the bodies own immune system to any foreign substances it encounters. Tumors are considered by the body to be foreign at it often requires a genetic mutation for cells to become cancerous. Cancers are able to circumvent these natural antibodies by various means but there is...

Doubles survival BUT "comparator" arm is best supportive care. See http://investor.poniard.com/ReleaseDetail.cfm?ReleaseID=306218

Xeloda has time after time demonstrated to be as good if not better than 5FU Xeloda continues to lag behind 5FU in the US Recent trial results are not likely to change things overnight

Novartis has a leading pipeline in cancer drugs and has staked their profits on the cancer market more than any of the major drug makers. The drug in question (ASA404) is a Non-small cell lung cancer treatment candidate, This cancer accounts for up to 90% of all lung cancers. Worldwide, lung cancer...

The p53 tumor suppressor gene is though to be a in-built protective agent for cells against their transforming into cancer cells. Loss of this gene during the cell’s life predisposes it to become cancerous. Potential therapies that may stop or reverse this loss of protection, may be beneficial in cancer...

Xeloda, an oral agent, was non-inferior to infusional 5-FU, when combined ith oxaliplatin in a randomized trial in patients with metastatic colrectal cancer (m-CRC) In fact, Xeloda containing regimen was assocaited with less myelosuppression, but more rashes and diaarhea. This is good news for...

In MCRC FOLFOX which involves infusional 5FU has been the cornerstone of therapy. This study shows that an oral 5FU substitute, Xeloda, can replace the IV 5FU and expedide care and avoid cumbersome infusions.

Lilly will likely get front line approval for Alimta in non small cell lung cancer Most patients with advanced disease never see a response to therapy

Novel therapy for advance recurrent prostate cancer that does not rely upon traditional standard hormone therapy. This has the potential for men to continue to be sexually active while receiving treatment for advanced disease.  It also opens the door to other therapeutic interventions.